[Form 4] Twist Bioscience Corp Insider Trading Activity

Rhea-AI Filing Summary

Patrick John Finn, President and COO of Twist Bioscience Corp (TWST), reported a sale of $29.161-priced common stock on 10/02/2025. The Form 4 shows 206 shares were sold to satisfy tax withholding obligations tied to vested Restricted Stock Units; the filing states these were mandatory 'sell to cover' transactions rather than discretionary trades. Following the transaction and an administrative correction, the reporting person beneficially owns 232,482 shares. The Form 4 was filed by counsel on 10/06/2025 and is signed by an attorney-in-fact.

Positive

• Sale was tax-withholding related, not a discretionary trade, indicating no active liquidation of stake
• Substantial retained ownership: beneficial ownership remains at 232,482 shares after adjustment
• Timely disclosure with an explanatory remark and attorney-in-fact signature filed on 10/06/2025

Negative

• None.

Insights

Equity Compensation Analyst

Small, routine sale to cover RSU taxes; ownership remains substantial.

The reported disposition of 206 shares at $29.161 is described as a mandatory sell-to-cover tied to vested Restricted Stock Units, which means the transaction was executed to satisfy tax withholding rather than as a voluntary cash sale. That mechanism is common when equity awards vest and the issuer elects to collect withholding by selling shares.

Retention of 232,482 shares after the adjustment preserves the officer's continued equity stake; monitor future scheduled vesting events or additional Form 4s in the near term (Q4 2025 timeframe) for any patterned sales beyond tax-related disposals.

Corporate Governance Specialist

Disclosure is routine and timely; administrative correction noted.

The Form 4 was filed within days of the transaction and includes an explicit explanation that the post-transaction balance was adjusted to correct an administrative error, which increases transparency about recordkeeping. The signature by an attorney-in-fact and the included remarks meet standard reporting formalities.

Investors should note that administrative corrections can change reported beneficial totals; expect corrected balances to be final unless further amendments appear in subsequent filings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		S		206(1)	D	$29.161	232,482(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. The balance has been adjusted to reduce the number of shares beneficially owned to correct an administrative error.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Twist Bioscience (TWST) Form 4 filed by Patrick John Finn disclose?

The filing discloses a sale of 206 shares on 10/02/2025 at $29.161 per share to satisfy tax withholding from vested Restricted Stock Units.

Was the sale by the TWST officer a discretionary trade?

No. The Form 4 states the sale was a mandatory 'sell to cover' to cover tax withholding obligations tied to RSU vesting.

How many TWST shares does Patrick John Finn beneficially own after the transaction?

The Form 4 reports a post-transaction beneficial ownership of 232,482 shares, adjusted to correct an administrative error.

When was the Form 4 for this insider transaction filed?

The Form 4 was signed by an attorney-in-fact and filed on 10/06/2025.

Why was the number of shares beneficially owned adjusted?

The filing explains the balance was reduced to correct an administrative error in prior reporting.